Cargando…

Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma

BACKGROUND: Partner of Sld five 3 (Psf3) is a member of the heterotetrameric complex that consists of SLD5, Psf1, Psf2, and Psf3. We have shown in previous studies that high Psf3 expression was a poor prognostic marker for pulmonary adenocarcinoma. Here, we statistically evaluated the relationship b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Kenji, Tanaka, Yugo, Tauchi, Shunsuke, Kitamura, Yoshitaka, Nishio, Wataru, Sakai, Yasuhiro, Hayashi, Yoshitake, Yoshimura, Masahiro, Maniwa, Yoshimasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885426/
https://www.ncbi.nlm.nih.gov/pubmed/31637868
http://dx.doi.org/10.1111/1759-7714.13230
_version_ 1783474735759228928
author Kimura, Kenji
Tanaka, Yugo
Tauchi, Shunsuke
Kitamura, Yoshitaka
Nishio, Wataru
Sakai, Yasuhiro
Hayashi, Yoshitake
Yoshimura, Masahiro
Maniwa, Yoshimasa
author_facet Kimura, Kenji
Tanaka, Yugo
Tauchi, Shunsuke
Kitamura, Yoshitaka
Nishio, Wataru
Sakai, Yasuhiro
Hayashi, Yoshitake
Yoshimura, Masahiro
Maniwa, Yoshimasa
author_sort Kimura, Kenji
collection PubMed
description BACKGROUND: Partner of Sld five 3 (Psf3) is a member of the heterotetrameric complex that consists of SLD5, Psf1, Psf2, and Psf3. We have shown in previous studies that high Psf3 expression was a poor prognostic marker for pulmonary adenocarcinoma. Here, we statistically evaluated the relationship between clinicopathologic factors and Psf3 expression in stage I pulmonary adenocarcinoma. METHODS: A total of 583 patients who had undergone complete resection of stage I pulmonary adenocarcinoma from January 2002 to December 2009 were included in the study. Tissue microarrays were performed, and the resected tumors were divided into groups according to Psf3 expression. RESULTS: Of 583 patients, high expression of Psf3 was observed in 211 (36.2%) and low expression of Psf3 observed in 372 (63.8%) patients. Among stage I patients, the five‐year survival rate was 76.7% in the Psf3 high expression group and 90.9% in the Psf3 low expression group (P < 0.0001). On multivariate analysis, Psf3 was found to be the independent prognostic factor. Among stage I patients in the Psf3 high expression group, a significantly greater five‐year survival rate was observed in patients who received postoperative chemotherapy with tegafur‐uracil than in those who underwent surgery alone (P < 0.0001). In contrast, among stage I patients in the Psf3 low expression group, no difference was found in the five‐year survival, regardless of the presence or absence of tegafur‐uracil (P = 0.873). CONCLUSION: The Psf3 expression was an independent prognostic factor and could be a biomarker of adjuvant tegafur‐uracil for stage I pulmonary adenocarcinoma. KEY POINTS: Significant findings of the study: The Psf3 expression could be a biomarker of adjuvant tegafur‐uracil administration for stage I pulmonary adenocarcinoma. What this study adds: Appropriate patients of adjuvant chemotherapy for stage I pulmonary adenocarcinoma using Psf3 expression could be selected.
format Online
Article
Text
id pubmed-6885426
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-68854262019-12-09 Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma Kimura, Kenji Tanaka, Yugo Tauchi, Shunsuke Kitamura, Yoshitaka Nishio, Wataru Sakai, Yasuhiro Hayashi, Yoshitake Yoshimura, Masahiro Maniwa, Yoshimasa Thorac Cancer Original Articles BACKGROUND: Partner of Sld five 3 (Psf3) is a member of the heterotetrameric complex that consists of SLD5, Psf1, Psf2, and Psf3. We have shown in previous studies that high Psf3 expression was a poor prognostic marker for pulmonary adenocarcinoma. Here, we statistically evaluated the relationship between clinicopathologic factors and Psf3 expression in stage I pulmonary adenocarcinoma. METHODS: A total of 583 patients who had undergone complete resection of stage I pulmonary adenocarcinoma from January 2002 to December 2009 were included in the study. Tissue microarrays were performed, and the resected tumors were divided into groups according to Psf3 expression. RESULTS: Of 583 patients, high expression of Psf3 was observed in 211 (36.2%) and low expression of Psf3 observed in 372 (63.8%) patients. Among stage I patients, the five‐year survival rate was 76.7% in the Psf3 high expression group and 90.9% in the Psf3 low expression group (P < 0.0001). On multivariate analysis, Psf3 was found to be the independent prognostic factor. Among stage I patients in the Psf3 high expression group, a significantly greater five‐year survival rate was observed in patients who received postoperative chemotherapy with tegafur‐uracil than in those who underwent surgery alone (P < 0.0001). In contrast, among stage I patients in the Psf3 low expression group, no difference was found in the five‐year survival, regardless of the presence or absence of tegafur‐uracil (P = 0.873). CONCLUSION: The Psf3 expression was an independent prognostic factor and could be a biomarker of adjuvant tegafur‐uracil for stage I pulmonary adenocarcinoma. KEY POINTS: Significant findings of the study: The Psf3 expression could be a biomarker of adjuvant tegafur‐uracil administration for stage I pulmonary adenocarcinoma. What this study adds: Appropriate patients of adjuvant chemotherapy for stage I pulmonary adenocarcinoma using Psf3 expression could be selected. John Wiley & Sons Australia, Ltd 2019-10-22 2019-12 /pmc/articles/PMC6885426/ /pubmed/31637868 http://dx.doi.org/10.1111/1759-7714.13230 Text en © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Kimura, Kenji
Tanaka, Yugo
Tauchi, Shunsuke
Kitamura, Yoshitaka
Nishio, Wataru
Sakai, Yasuhiro
Hayashi, Yoshitake
Yoshimura, Masahiro
Maniwa, Yoshimasa
Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma
title Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma
title_full Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma
title_fullStr Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma
title_full_unstemmed Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma
title_short Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma
title_sort psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885426/
https://www.ncbi.nlm.nih.gov/pubmed/31637868
http://dx.doi.org/10.1111/1759-7714.13230
work_keys_str_mv AT kimurakenji psf3asapossiblebiomarkerofpostoperativechemotherapyforpatientswithearlypulmonaryadenocarcinoma
AT tanakayugo psf3asapossiblebiomarkerofpostoperativechemotherapyforpatientswithearlypulmonaryadenocarcinoma
AT tauchishunsuke psf3asapossiblebiomarkerofpostoperativechemotherapyforpatientswithearlypulmonaryadenocarcinoma
AT kitamurayoshitaka psf3asapossiblebiomarkerofpostoperativechemotherapyforpatientswithearlypulmonaryadenocarcinoma
AT nishiowataru psf3asapossiblebiomarkerofpostoperativechemotherapyforpatientswithearlypulmonaryadenocarcinoma
AT sakaiyasuhiro psf3asapossiblebiomarkerofpostoperativechemotherapyforpatientswithearlypulmonaryadenocarcinoma
AT hayashiyoshitake psf3asapossiblebiomarkerofpostoperativechemotherapyforpatientswithearlypulmonaryadenocarcinoma
AT yoshimuramasahiro psf3asapossiblebiomarkerofpostoperativechemotherapyforpatientswithearlypulmonaryadenocarcinoma
AT maniwayoshimasa psf3asapossiblebiomarkerofpostoperativechemotherapyforpatientswithearlypulmonaryadenocarcinoma